Your browser doesn't support javascript.
loading
Automatic Implantable Cardioverter Defibrillator (AICD) Implantation as Secondary Prevention of Cardiac Sarcoidosis-Associated Ventricular Tachycardia.
Saliba, Fares; Mina, Jonathan; Aoun, Laurence; Khattar, Georges; Bou Sanayeh, Elie; Mourad, Omar; Abu Baker, Saif.
Afiliación
  • Saliba F; Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA.
  • Mina J; Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA.
  • Aoun L; Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA.
  • Khattar G; Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA.
  • Bou Sanayeh E; Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA.
  • Mourad O; Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA.
  • Abu Baker S; Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA.
Eur J Case Rep Intern Med ; 11(6): 004469, 2024.
Article en En | MEDLINE | ID: mdl-38846646
ABSTRACT

Background:

Cardiac sarcoidosis can cause a wide range of symptoms, including shortness of breath, chest pain, oedema, and fatal arrhythmias such as ventricular tachycardia (VT). Because the symptoms can be nonspecific, diagnosing cardiac sarcoidosis can be challenging. Treatment options may include corticosteroids to reduce inflammation, immunosuppressive drugs to prevent further damage, medications to control symptoms, ablation procedures, and defibrillators to prevent cardiac arrest. Case A 60-year-old woman who has sarcoidosis affecting multiple organs including cardiac sarcoidosis, non-ischemic cardiomyopathy with reduced ejection fraction, and hypertension, was admitted with tachycardia, shortness of breath, and a recently fired automatic implantable cardioverter defibrillator (AICD). Three months prior, the patient was admitted for a syncopal episode and diagnosed with cardiac sarcoidosis through cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET), which demonstrated active inflammation, and an AICD was implanted. During this admission, the patient had an episode of ventricular tachycardia and was treated with amiodarone and lidocaine. The patient received steroids, sacubitril/valsartan, and methotrexate. After 48 hours of observation, the patient was discharged without further events.

Conclusion:

Cardiac sarcoidosis is a rare but serious disease that can lead to life-threatening cardiac complications such as ventricular tachycardia. Early diagnosis and aggressive management are crucial for improving outcomes and preventing sudden cardiac death. AICD implantation as a secondary prevention in cardiac sarcoidosis might prevent cardiac arrest." LEARNING POINTS Cardiac sarcoidosis can present with non-specific symptoms and lead to life-threatening arrhythmias such as ventricular tachycardia, emphasising the importance of early diagnosis and aggressive management to prevent sudden cardiac death.A multidisciplinary approach involving imaging modalities such as cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, along with histological findings, is crucial for accurately diagnosing cardiac sarcoidosis, as endomyocardial biopsy alone has low sensitivity.Implantation of an automatic implantable cardioverter defibrillator (AICD) as a secondary prevention measure should be considered in cardiac sarcoidosis patients, even in elderly individuals with mildly to moderately reduced ejection fraction, to prevent fatal arrhythmias and sudden cardiac death.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Case Rep Intern Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Case Rep Intern Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...